Yttrium-90 radioembolization for unresectable liver metastases of melanoma:efficacy and safety / 中华肝胆外科杂志

ABSTRACT

Studies correlated with yttrium-90 ( 90 Y) radioembolization for unresectable liver metasta-ses of melanoma ( LMM) were analyzed during January 1st, 1991 to September 1st, 2018. A total of 9 reports involving 207 patients were included for the analysis. The most common primary site of melanoma was choroid, followed by cutaneous and rectal. A total of 199 cases were followed-up, and in 181 patient the complete response rate was 1. 1％(2/181), partial response rate was 18. 2％(33/181), stable disease rate was 46. 4％ ( 84/181 ) , and cancer control rate was 65. 7％ ( 119/181 ) . The median survival was 10 months. Complications were found in 42 cases (21. 5％, 42/195), including radioembolization induced liver disease ( n =39 ) , gastric ulceration ( n =2 ) , cholecystitis ( n =1 ) , and liver failure ( n =3 ) . Adverse reaction included fatigue ( 14. 3％ ～44. 0％) , nausea ( 6. 3％ ～23. 0％) , and abdominal pain (7. 0％ ～38. 0％). 90Y radioembolization is a promising alternative therapy for the treatment of unresectable LMM, with encouraging effects on disease control and survival. Some complications can occur, and adverse reaction are frequent but mild.